SCHEMBL851440

SCHEMBL851440

CCCCC#CCCCC(=O)O

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN7 P35236 5/20 0.77
TDP1 Q9NUW8 4/20 0.77
ALDH1A1 P00352 3/20 0.77
RECQL P46063 2/20 0.77
MEN1 O00255 2/20 0.77
KMT2A Q03164 2/20 0.77
KDM4E B2RXH2 1/20 0.77
USP2 O75604 1/20 0.77
POLB P06746 1/20 0.77
MAPT P10636 1/20 0.77
HPGD P15428 1/20 0.77
ALOX12 P18054 1/20 0.77
BLM P54132 1/20 0.77
MCL1 Q07820 1/20 0.77
SMN1; SMN2 Q16637 1/20 0.77
HMGCR P04035 3/20 0.76
AKR1B1 P15121 1/20 0.61
EPHX2 P34913 2/20 0.61
PPARG P37231 6/20 0.58
PPARD Q03181 6/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10916054 0.94 PTPN7 (0.89) PTPN7TDP1ALDH1A1RECQLMEN1
SCHEMBL3626030 0.93 PTPN7 (0.88) PTPN7TDP1ALDH1A1RECQLMEN1
SCHEMBL31189075 0.93 PTPN7 (0.88) PTPN7TDP1ALDH1A1RECQLMEN1
SCHEMBL3625223 0.91 PTPN7 (0.92) PTPN7TDP1ALDH1A1RECQLMEN1
SCHEMBL5375247 0.91 PTPN7 (0.92) PTPN7TDP1ALDH1A1RECQLMEN1
SCHEMBL30163354 0.91 PTPN7 (0.92) PTPN7TDP1ALDH1A1RECQLMEN1
SCHEMBL414803 0.91 HMGCR (0.85) PTPN7TDP1ALDH1A1RECQLMEN1
SCHEMBL2734268 0.91 PTPN7 (0.92) PTPN7TDP1ALDH1A1RECQLMEN1
SCHEMBL3626332 0.91 PTPN7 (0.92) PTPN7TDP1ALDH1A1RECQLMEN1
SCHEMBL10487275 0.91 PTPN7 (0.92) PTPN7TDP1ALDH1A1RECQLMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120053660-A Hydrophilic complex for preventing, preventing or treating microbial infection, preparation and application thereof 太阳雨林(北京)生物医药有限公司 2025-05-30 CN disclosed
CN-120053661-A Hydrophilic fatty acid complex for preventing, preventing or treating microbial infection, preparation and application thereof 太阳雨林(北京)生物医药有限公司 2025-05-30 CN disclosed
CN-119855607-A Carbon chain substance for regulating transmembrane transport and fluidity of cell membrane, preparation and application 太阳雨林(北京)生物医药有限公司 2025-04-18 CN disclosed
EP-4520348-A1 CARBON CHAIN SUBSTANCE FOR REGULATING TRANSMEMBRANE TRANSPORT AND FLUIDITY OF CELL MEMBRANES, AND PREPARATION AND USE THEREOF Sunforest (Beijing) Biopharma Ltd (CN) 2025-03-12 EP disclosed
WO-2023213310-A9 CARBON CHAIN SUBSTANCE FOR REGULATING TRANSMEMBRANE TRANSPORT AND FLUIDITY OF CELL MEMBRANES, AND PREPARATION AND USE THEREOF 太阳雨林(北京)生物医药有限公司 2025-02-20 WO disclosed
WO-2023213310-A1 CARBON CHAIN SUBSTANCE FOR REGULATING TRANSMEMBRANE TRANSPORT AND FLUIDITY OF CELL MEMBRANES, AND PREPARATION AND USE THEREOF 太阳雨林(北京)生物医药有限公司 2023-11-09 WO disclosed
CN-115607677-A Compound for preventing, preventing or treating microbial infection and preparation and application thereof 太阳雨林(北京)生物医药有限公司 2023-01-17 CN disclosed
CN-114569726-B Compound for preventing, preventing or treating microbial infection and preparation method and application thereof 太阳雨林(北京)生物医药有限公司 2022-10-28 CN disclosed
CN-114788872-A Compound for preventing, preventing or treating microbial infection and preparation and application thereof 太阳雨林(北京)生物医药有限公司 2022-07-26 CN disclosed
CN-114569726-A Compound for preventing, preventing or treating microbial infection and preparation method and application thereof 太阳雨林(北京)生物医药有限公司 2022-06-03 CN disclosed
US-20120270838-A1 SPIROIMIDAZOLONE DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2012-10-25 US disclosed
EP-2433940-A1 SPIROIMIDAZOLONE DERIVATIVE Chugai Seiyaku Kabushiki Kaisha (JP) 2012-03-28 EP disclosed
EP-2433940-A1 SPIROIMIDAZOLONE DERIVATIVE Chugai Seiyaku Kabushiki Kaisha (JP) 2012-03-28 EP disclosed
WO-2010126030-A1 SPIROIMIDAZOLONE DERIVATIVE 中外製薬株式会社 (JP) 2010-11-04 WO disclosed
CN-1215835-C Ketone derivatives and medical use thereof TORAY INDUSTRIES (JP) 2005-08-24 CN disclosed
US-6215016-B1 HEMATOPOIETIC AGENTS; PREVENTING CYTOPENIA TORAY INDUSTRIES, INC. (JP) 2001-04-10 US disclosed
CN-1194580-A Ketone derivatives and medical use thereof TORAY INDUSTRIES (JP) 1998-09-30 CN disclosed
EP-0841063-A1 KETONE DERIVATIVES AND MEDICINAL USE THEREOF TORAY INDUSTRIES, INC. (JP) 1998-05-13 EP disclosed
US-4605645-A ANTITUMOR AGENTS TEIJIN LIMITED (JP) 1986-08-12 US disclosed
EP-0081386-A1 5-Fluoro-2'-deoxyuridine derivatives and a process for the preparation thereof TEIJIN LIMITED (JP) 1983-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120270838-A1 SPIROIMIDAZOLONE DERIVATIVE WNK3, REN, SGK3 PTPN7 1044/4885TDP1 3062/4885ALDH1A1 836/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.